OncLive SOSS

Evolving Treatments in Hepatocellular Carcinoma: Updates from ASCO GI 2024 - Episode 5

EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

March 11, 2024

Drs Gong and Covey emphasize the impact of TACE + durvalumab ± bevacizumab combination therapy surrounding HCC treatment strategy.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Hepatocellular Carcinoma (HCC) Disease State Overview

EP. 2: Utilizing Interventional Radiology and Liver-directed Therapies

EP. 3: Determining Transarterial Chemoembolization (TACE) Candidacy for Patients with HCC

EP. 4: EMERALD-1 Study: Significance as Presented at ASCO GI 2024

EP. 5: EMERALD-1 Study: Outshining Negative Clinical Trials Based Upon TKI- and Liver-directed Therapies

EP. 6: IMBrave-050 Study Overview

EP. 7: Patient Profile 1: Advanced HCC Treated with Durvalumab and Tremelimumab

EP. 8: HIMALAYA Study in Advanced Stage HCC

EP. 9: Establishing Optimal HCC Treatment Strategy

EP. 10: IMBrave150 Study Overview

EP. 11: HCC Treatment Strategy Driven by Real-World Evidence

EP. 12: Combining Liver-directed and Systemic Therapies in HCC

EP. 13: Patient Profile 2: Patient Progression After Frontline HCC Therapy

EP. 14: CARES-310 Trial: Impressions and Clinical Impact on HCC Treatment Landscape

EP. 15: REGONEXT Study: Driving Second-line HCC Treatment Strategy

EP. 16: Trajectory of Evolving HCC Treatment Landscape

x